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Since the first evidence of malignancy in cerebrospinal fluid 
(CSF) was reported in 1904, CSF examination has been used to 
diagnose numerous neoplastic diseases of the central nervous 
system (CNS).1 In patients with CNS metastasis, diagnostic 
confirmation is provided mostly through CSF cytology and 
serves to verify the presence of malignancy.2,3 As most secondary 
CNS tumors spread along the leptomeningeal space and com-
municate with the ventricles or subarachnoid space, it is gener-
ally not difficult to detect malignant cells in the CSF. Several 
studies concerning the diagnostic accuracy of CSF cytology 
have been reported.4-6 In those previous studies, however, CSF 
collection and examination were performed only once per pa-
tient, and the results varied greatly depending on the sampling 
time. Moreover, it is difficult to judge patient status using a 
single cytological examination because continuous adjuvant 
therapies are routinely performed.7 To determine the practical 
use and reproducibility of diagnoses based on CSF cytology, we 
evaluated this test by analyzing cytology results from consecu-
tive CSF samples.
MATERIALS AND METHODS
Patient selection
Between July 2010 and June 2013, 385 CSF cytology sam-
ples were collected from 42 patients with the presence of a met-
astatic tumor confirmed by at least two histologic or cytological 
studies. Cytology samples obtained before adjuvant therapies 
were excluded to evaluate the diagnostic rate of CSF cytology 
more consistently. The breakdown of the patient population 
was as follows: 25 males and 17 females, with a median age of 
55 years (range, 29 to 77 years). The mean observation period 
was 5 months (range, 1 to 22 months), and the mean number 
of CSF examinations was 9 (range, 2 to 34).
Cerebrospinal fluid specimen collection and cytology slide 
preparation
All patients underwent an operation for the placement of a 
ventricular catheter and reservoir as well as consecutive CSF col-
lections using the reservoir (Fig. 1). To minimize dry artifacts 
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and prevent cell degeneration, samples were delivered to the 
Department of Pathology immediately upon collection. Sam-
ples were then processed using liquid-based cytology (LBC) 
(ThinPrep, Cytyc Co., Boxborough, MA, USA), an automated 
method of preparation and smearing of cells in a monolayer. 
Slides were stained and evaluated with the Papanicolaou stain-
A B
Fig. 1. Operation for ventricular catheter and reservoir placement. A localized area of the skull is removed (A), and the reservoir is placed in 
the defect area (B).
A B
C D
Fig. 2. Low (A) and high (B) power views of cerebrospinal fluid in a patient with metastatic adenocarcinoma of the lung. Separate case 
showing an atypical cell (C) confirmed as metastatic carcinoma using immunocytochemistry for cytokeratin (D).
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ing method. Of the 385 CSF samples, 54 were processed by a 
conventional smear method rather than the liquid-based meth-
od because those samples were obtained when the liquid-based 
method was not available for CSF cytology. 
Immunocytochemistry
Immunocytochemistry (ICC) was performed using a Ventana 
XT automated stainer (Ventana Co., Tucson, AZ, USA) with an 
antibody to cytokeratin (1:300, AE1/AE3, Dako, Carpinteria, 
CA, USA). Slides were incubated with primary antibody for 32 
minutes at 37°C followed by a universal secondary antibody for 
8 minutes at 37°C. Slides were incubated in streptavidin-horse-
radish peroxidase D for 16 minutes at 37°C, and then the sub-
strate, 3,3’-diaminobenzidine tetrahydrochloride (DAB) H2O2, 
was added for 8 minutes, followed by hematoxylin and bluing 
reagent counterstains at 37°C.
Table 1. Clinicopathologic features of 42 cases and diagnostic rates of cerebrospinal fluid cytology
Case No. Sex Age (yr) Primary site Histologic type Period (mo) Total Negative rate Positive rate
  1 M 48 Lung Adenocarcinoma 1 6 3 (50.0) 3 (50.0)
  2 M 63 Lung Adenocarcinoma 1 4 2 (50.0) 2 (50.0)
  3  F 60 Ovary Serous papillary carcinoma 8 13 10 (76.9) 3 (23.1)
  4 M 64 Lung Adenocarcinoma 2 13 7 (53.8) 6 (46.2)
  5 M 56 Rectum Adenocarcinoma 7 12 12 (100.0) 0 (0)
  6 F 56 Breast Invasive ductal carcinoma 5 11 10 (90.9) 1 (9.1)
  7 F 43 Lung Adenocarcinoma 3 13 8 (61.5) 5 (38.5)
  8 M 58 Lung Adenocarcinoma 11 22 19 (86.0) 3 (14.0)
  9 M 52 Kidney Renal cell carcinoma 5 9 9 (100.0) 0 (0.0)
10 F 66 Lung Adenocarcinoma 22 22 21 (95.5) 1 (4.5)
11 M 66 Lung Adenocarcinoma 1 2 0 (0.0) 2 (100.0)
12 M 58 Lung Adenocarcinoma 2 15 5 (33.3) 10 (66.7)
13 M 62 Lung Adenocarcinoma 21 34 18 (52.9) 16 (47.1)
14 M 65 Stomach Adenocarcinoma 1 7 2 (28.6) 5 (71.4)
15 M 66 Lung Adenocarcinoma 6 15 12 (80.0) 3 (20.0)
16 F 58 Lung Adenocarcinoma 4 17 11 (64.7) 6 (35.3)
17 M 29 Stomach Signet ring cell carcinoma 3 9 4 (44.4) 5 (55.6)
18 M 51 Lung Adenocarcinoma 1 3 0 (0.0) 3 (100.0)
19 F 71 Lung Adenocarcinoma 1 4 1 (25.0) 3 (75.0)
20 F 74 Ovary Serous papillary carcinoma 3 8 0 (0.0) 8 (100.0)
21 M 64 Stomach Adenocarcinoma 1 4 0 (0.0) 4 (100.0)
22 M 52 Lung Adenocarcinoma 1 8 1 (12.5) 7 (87.5)
23 F 58 Stomach Adenocarcinoma 1 3 0 (0.0) 3 (100.0)
24 M 65 Lung Adenocarcinoma 9 14 12 (85.7) 2 (14.3)
25 F 47 Breast Invasive ductal carcinoma 1 2 0 (0.0) 2 (100.0)
26 F 40 Breast Invasive ductal carcinoma 11 7 2 (28.6) 5 (71.4)
27 F 56 Breast Invasive ductal carcinoma 1 2 0 (0.0) 2 (100.0)
28 M 65 Lung Small cell carcinoma 4 4 3 (75.0) 1 (25.0)
29 M 51 Skin Malignant melanoma 1 2 0 (0.0) 2 (100.0)
30 F 46 Breast Invasive ductal carcinoma 5 18 17 (94.4) 1 (5.6)
31 M 55 Urinary bladder Urothelial carcinoma 1 2 1 (50.0) 1 (50.0)
32 M 41 Lung Adenocarcinoma 2 11 3 (27.3) 8 (72.7)
33 M 53 Lung Adenocarcinoma 2 8 7 (87.5) 1 (12.5)
34 M 55 Lung Adenocarcinoma 8 7 1 (14.3) 6 (85.7)
35 F 46 Breast Invasive ductal carcinoma 5 3 3 (100.0) 0 (0.0)
36 M 39 Pancreas Adenocarcinoma 6 7 5 (71.4) 2 (28.6)
37 F 65 Breast Invasive ductal carcinoma 5 13 6 (46.2) 7 (53.8)
38 M 31 Skin Malignant melanoma 2 4 3 (75.0) 1 (25.0)
39 F 46 Breast Invasive ductal carcinoma 1 4 2 (50.0) 2 (50.0)
40 F 49 Lung Adenocarcinoma 10 8 3 (37.5) 5 (62.5)
41 M 49 Lung Adenocarcinoma 1 9 0 (0.0) 9 (100.0)
42 F 77 Lung Adenocarcinoma 1 6 3 (50.0) 3 (50.0)
Mean 5 385 226 (58.7) 159 (41.3)
Values are presented as number (%).
M, male; F, female.
http://www.koreanjpathol.org http://dx.doi.org/10.4132/KoreanJPathol.2013.47.6.563
566 • Bae YS, et al.
Interpretation criteria
Cases without atypical cells suggestive of metastasis were di-
agnosed as negative for malignancy. A positive diagnosis of ma-
lignancy was defined as the presence of atypical cells with cyto-
keratin immunoreactivity, regardless of the amount (Fig. 2). 
There were some cases that presented with atypical cells on Pa-
panicolaou-stained slides, but it was not possible to evaluate 
many of these cases using cytokeratin ICC slides because the 
cells disappeared during the staining process. In those cases, we 
termed the diagnosis suspicious for malignancy, and these cases 
were regarded as positive findings when calculating the diag-
nostic rates. All slides, including those for ICC, were indepen-
dently reviewed by two pathologists (S.H.K and Y.S.B). 
RESULTS
As summarized in Table 1, primary malignancy sites were di-
verse. Lung was the most common primary site with 22 cases, 
followed by breast with 6 cases. The histologic types of primary 
malignancies are shown in Table 1. Of the 385 specimens, 132 
were diagnosed as positive for malignancy and 27 were suspi-
cious for malignancy, for a total of 159 specimens considered to 
have a positive diagnosis of malignancy. Among the 42 patients, 
3 were never diagnosed as malignant by cytology examination 
even though all were confirmed to have CNS metastasis on 
brain tissue biopsy. Eight patients were consistently diagnosed 
as positive for malignancy in serial CSF evaluations. The posi-
tive malignancy diagnosis rates in the other 31 patients ranged 
from 4.5% to 87.5%, and the mean positive rate was 41.3%. 
Table 2 demonstrates two representative cases (case nos. 4 
and 12) from our series. During a period of two months, these 
two patients underwent 13 and 15 CSF cytology examinations, 
which yielded positive results in 6 and 10 of the tests, respec-
tively. The intervals between CSF cytology examinations ranged 
from 0 to 13 days and were short enough to enable more metic-
ulous analysis of consecutive diagnostic rates. However, the re-
sults appeared random, without a consistent trend. Even within 
the same day, the diagnoses made from two specimens were dif-
ferent.
DISCUSSION
Rapid transport is important for optimal cellular preservation 
in CSF materials, which can be cytolysed quickly. In order to re-
duce the number of nondiagnostic cases, CSF materials should 
be examined as soon as possible after collection. From a routine 
diagnostic viewpoint, degeneration is one of the most problem-
atic artifacts when diagnosing cytology slides, as CSF specimens 
tend to degenerate more readily than other cytology specimens. 
These artifacts can affect the diagnostic accuracy and reduce 
specimen adequacy. We were able to control artificial factors by 
reminding clinicians of the importance of rapid processing and 
encouraging them to submit the samples immediately.
Most previous studies concerning the diagnostic rates of CSF 
examination used the lumbar puncture as a diagnosing modali-
ty.4-6 However, lumbar puncture can be harmful to patients and 
difficult for clinicians because it is an invasive procedure. It is 
this for reason that most previous studies regarding the diag-
nostic accuracy of CSF performed only one CSF examination per 
patient. In this study, however, consecutive CSF sampling was 
performed using the ventricular catheter and reservoir from 
Table 2. Consecutive cerebrospinal fluid cytology results of case no. 4 and case no. 12
Case No. 4 Cytological diagnosis Date Case No. 12 Cytological diagnosis Date
  1 Negative for malignancy Oct 20, 2010   1 Positive for malignancy Feb 5, 2013
  2 Positive for malignancy Oct 23, 2010   2 Positive for malignancy Feb 15, 2013
  3 Negative for malignancy Oct 30, 2010   3 Negative for malignancy Feb 25, 2013
  4 Positive for malignancy Nov 2, 2010   4 Positive for malignancy Feb 27, 2013
  5 Positive for malignancy Nov 8, 2010   5 Positive for malignancy Mar 5, 2013
  6 Negative for malignancy Nov 10, 2010   6 Positive for malignancy Mar 6, 2013
  7  Suspicious for malignancy Nov 23, 2010   7 Negative for malignancy Mar 12, 2013
  8 Positive for malignancy Nov 24, 2010   8 Positive for malignancy Mar 14, 2013
  9 Negative for malignancy Nov 24, 2010   9 Positive for malignancy Mar 18, 2013
10 Negative for malignancy Dec 1, 2010 10 Negative for malignancy Mar 21, 2013
11 Suspicious for malignancy Dec 3, 2010 11 Positive for malignancy Mar 26, 2013
12 Negative for malignancy Dec 9, 2010 12 Negative for malignancy Mar 27, 2013
13 Negative for malignancy Dec 16, 2010 13 Positive for malignancy Mar 29, 2013
14 Negative for malignancy Apr 2, 2013
15 Positive for malignancy Apr 3, 2013
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each patient. Although a neurosurgical procedure is required to 
implant a ventricular catheter in patients, it enables the contin-
uous collection of CSF and consecutive analysis. 
LBC is now a widely used method for preparing cytology 
samples and has achieved broad acceptance for most cytology 
specimens.8-11 Furthermore, for the diagnosis of metastatic tu-
mors in CSF, thin-layer LBC has been suggested as an appropri-
ate diagnostic method.12,13 As in immunohistochemistry, ICC 
improves the diagnostic rates because cytology is often difficult 
and problematic to evaluate using cellular morphology alone.14 
Using LBC is more convenient for performing ICC than con-
ventional smear techniques, and the diagnostic efficacy of ICC 
on smears processed by thin-layer LBC has been previously vali-
dated.15-17
Up to the present time, there have been several reports re-
garding the diagnostic accuracy of CSF cytology in patients 
with CNS metastasis. Wasserstrom et al.5 reported a sensitivity 
of 54.4% in initial examination and 91.1% in subsequent ex-
amination. Gondos and King6 also reported a sensitivity of 
53.3%. Even though we used implanted ventricular catheters 
when obtaining CSF and LBC when preparing CSF slides, re-
sults of our study showed much lower diagnostic rates than 
previous studies. The discrepancy between results of previous 
studies and ours might be due to the different process of gath-
ering CSF; unlike previous studies, we tried to evaluate the di-
agnostic rates of CSF cytology using consecutive examination of 
CSF samples from each patient. Moreover, in our study, samples 
were obtained from patients receiving adjuvant treatments such 
as chemotherapy and radiation therapy, which may have affect-
ed the diagnostic rates of CSF analysis. From the viewpoint of 
daily practice, our results may be more practical and accurate 
because most patients with CNS metastasis are now managed 
with ancillary treatments.7
We could not analyze the results of CSF examinations with 
statistics of sensitivity or specificity because not all cytology 
specimens had a concordant tissue biopsy. In other words, the 
negative findings could not be directly considered as false nega-
tives because we could not completely exclude the possibility 
that the negative findings resulted from true tumor regression 
due to adjuvant therapies. However, as shown in Table 2, re-
sults were distributed unevenly although all examinations were 
performed within very short intervals, even within the same 
day in some cases. Therefore, we suggest that the negative find-
ings are not the results of tumor regression but false negative 
results. If so, the value of 41.3% can be regarded as sensitivity 
of CSF cytology in patients being treated with adjuvant thera-
pies due to CNS metastasis.
Several possible explanations exist for the negative results. 
First, several factors influencing the quality of CSF cytology 
specimens should be investigated. In our study, cytology speci-
mens from positive cases were more cellular than those from 
negative cases. However, this cannot be the reason for the nega-
tive results because CSF is physiologically acellular. The volume 
of the submitted specimen can affect the diagnostic accuracy, 
but unfortunately this aspect was not evaluable because the 
amount of fluid was not promptly recorded. Dry artifact is one 
of the most important factors in determining the quality of CSF 
slides. As mentioned earlier, we could maintain the quality of 
CSF cytology by notifying clinicians of the importance of rapid 
transport. However, specimen transport could not be controlled 
precisely and evenly because the specimens were transported by 
different clinicians with different time intervals. There was no 
significant difference among negative results when grouped ac-
cording to the sites of primary tumors (data not shown). Taken 
together, the negative results should be regarded as a multifac-
torial phenomenon without a specific reason.
Temporary CSF cytology examinations are no longer suffi-
cient for estimating clinical course because chemotherapy and 
optional radiotherapy are generally standard treatment modali-
ties in patients with CNS metastasis. Although the total num-
ber of cases included was not remarkable, this study is notewor-
thy in that we tried to evaluate the diagnostic rates of CSF cy-
tology in a novel way. By analyzing consecutive CSF samples 
obtained within short-term intervals, we were able to evaluate 
the diagnostic rates of CSF examination more precisely and 
more practically. Although the sensitivity of CSF cytology as a 
diagnostic tool in patients with CNS metastasis was lower than 
expected, even with the ICC, we consider this result to be im-
portant and instructive as negative results should not be ig-
nored or regarded as tumor regression. Alternatively, continu-
ous follow-up using CSF cytology is essential for determining 
clinical course, and the results must be interpreted in conjunc-
tion with clinical and radiological findings.
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